At March 31, 2025, the Company had $21.1 million in cash and cash equivalents as compared to $20.3 million in cash and cash ...

Emrosi commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoin ...

Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress”), an innovative biopharmaceutical company focused on acquiring and ...

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year ...

The most significant driver of the stock’s surge in 2025 has been the U.S. Food and Drug Administration approval and commercial launch of Emrosi, a 40 mg minocycline hydrochloride modified-release ...

a 40 mg minocycline hydrochloride modified-release capsule for the treatment of rosacea. The FDA approved Emrosi in November 2024, ahead of the scheduled PDUFA date, and the company began initial ...

a 40 mg minocycline hydrochloride modified-release capsule for the treatment of rosacea. The FDA approved Emrosi in November 2024, ahead of the scheduled PDUFA date, and the company began initial ...

The FDA approved three natural food dyes this week amid its transition away from petroleum-based dyes in the food supply. The colors "will expand the palette of available colors from natural ...

Instead, FDA Commissioner Marty Makary told reporters last month that the agency will be accelerating the review and approval of some new natural color additives. Here are the latest "natural ...